Free Trial
OTCMKTS:XSNX

NovAccess Global Q4 2024 Earnings Results & Report

NovAccess Global logo
$0.0001 0.00 (-50.00%)
As of 03:39 PM Eastern

NovAccess Global reported Q4 2024 earnings on January 14, 2026. The company reported EPS of -$0.06.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes

NovAccess Global EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NovAccess Global Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NovAccess Global Q4 2024 Earnings FAQ

NovAccess Global (OTCMKTS:XSNX) reported earnings of -$0.06 per share for Q4 2024. The report was announced on Wednesday, January 14, 2026.

NovAccess Global Earnings Headlines

NovAccess Global
Global wage calculator: Compare your salary
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
NovAccess Global Inc.
NovAccess Global Inc. (XSNX)
See More NovAccess Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovAccess Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovAccess Global and other key companies, straight to your email.

About NovAccess Global

NovAccess Global (OTCMKTS:XSNX), a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

View NovAccess Global Profile